Literature DB >> 21147903

Cervical cancer.

Benjamin E Greer, Wui-Jin Koh, Nadeem R Abu-Rustum, Sachin M Apte, Susana M Campos, John Chan, Kathleen R Cho, Larry Copeland, Marta Ann Crispens, Nefertiti Dupont, Patricia J Eifel, David K Gaffney, Warner K Huh, Daniel S Kapp, John R Lurain, Lainie Martin, Mark A Morgan, Robert J Morgan, David Mutch, Steven W Remmenga, R Kevin Reynolds, William Small, Nelson Teng, Fidel A Valea.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21147903     DOI： 10.6004/jnccn.2010.0104

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  24 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy.

Authors:  Cem Onal; Mehmet Reyhan; Ozan C Guler; Ali Fuat Yapar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells.

Authors:  Zhengzhe An; Jae-Ran Yu; Woo-Yoon Park
Journal:  Radiat Environ Biophys       Date:  2017-02-09       Impact factor: 1.925

4.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Knowledge and acceptability of human papillomavirus vaccination and cervical cancer screening among women in Karnataka, India.

Authors:  Martha P Montgomery; Tanaka Dune; Prasanna K Shetty; Avinash K Shetty
Journal:  J Cancer Educ       Date:  2015-03       Impact factor: 2.037

6.  c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.

Authors:  Tamer Refaat; Eric D Donnelly; Sean Sachdev; Vamsi Parimi; Samar El Achy; Prarthana Dalal; Mohamed Farouk; Natasha Berg; Irene Helenowski; Jeffrey P Gross; John Lurain; Jonathan B Strauss; Gayle Woloschak; Jian-Jun Wei; William Small
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

Review 7.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

8.  Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancer.

Authors:  Ruth A Kleinerman; Susan A Smith; Eric Holowaty; Per Hall; Eero Pukkala; Leila Vaalavirta; Marilyn Stovall; Rita Weathers; Ethel Gilbert; Berthe M P Aleman; Magnus Kaijser; Michael Andersson; Hans Storm; Heikki Joensuu; Charles F Lynch; Graça M Dores; Lois B Travis; Lindsay M Morton; Rochelle E Curtis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-22       Impact factor: 7.038

Review 9.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

10.  Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes.

Authors:  Buyuan Chen; Xinji Chen; Xiwei Wu; Xiaoling Wang; Yingjia Wang; Ting-Yu Lin; Jessica Kurata; Jun Wu; Steven Vonderfecht; Guihua Sun; He Huang; Jiing-Kuan Yee; Jianda Hu; Ren-Jang Lin
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.